Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Acerus Pharmaceuticals Corporation (T:ASP)

Business Focus: Pharmaceuticals (NEC)

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for ASP within the last 6 months
See all filings within the past 6 months

Company News

Jun 27, 2022 17:30 ET
Acerus Announces Voting Results for the 2022 Annual Meeting
Acerus Pharmaceuticals Corporation (“Acerus”) (TSX: ASP; OTCQB: ASPCF) today announced the voting results from its annual meeting of shareholders held on June 27, 2022. The total number of shares represented in person or by proxy at the meeting was...
Read full article
Jun 24, 2022 07:30 ET
Acerus Announces Amendments to Loan Facility
Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced that it has entered into an amending agreement with First Generation Capital Inc. (“First Generation”), a company affiliated with the Chairman of...
Read full article
See more news stories

Valuation Ratios

Price to Sales - TTM
Price to Book - most recent quarter
Price to Cash Flow per share - TTM
Price to Free Cash Flow per share - TTM
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Jun 15, 202225939
May 31, 2022220-908
May 15, 20221,128854
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

Acerus Pharmaceuticals Corporation is a Canada-based specialty pharmaceutical company. The Company is focused on the commercialization and development of prescription products with a primary focus in the field of men's health. Its product, Natesto, is a testosterone nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism. It has two product pipelines, such as avanafil, which is a chemical entity PDE5 inhibitor for the treatment of erectile dysfunction and Lidbree, is a short acting lidocaine formulation delivered through a device into the vaginal mucosal tissue. It also has product rights to Tefina, a clinical stage product aimed at addressing an unmet need for women with female sexual dysfunction. Its non-prescription product includes Elegant, which is a vaginal moisturizer. Its primary market is the United States where it commercializes its product with their contract commercial provider Syneos Health (Syneos).

See business summary



Search (past week) for $ASP.CA

  • No tweets found